文献速递临床试验与 GCP流行病学与生物统计

药物洗脱支架经皮冠状动脉介入治疗后双联抗血小板治疗时程:系统综述与网络Meta分析

Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis.
PubMed 文献 · BMJ · 2019-06-28

该系统综述与网络Meta分析纳入17项随机对照试验(n=46 864),比较药物洗脱支架PCI术后短期(<6个月)、标准(12个月)与长期(>12个月)双联抗血小板治疗。长期DAPT较短期增加大出血(OR 1.78,95%CI 1.27-2.49)和非心源性死亡(OR 1.63,95%CI 1.03-2.59);标准DAPT较短期增加任何出血(OR 1.39,95%CI 1.01-1.92)。作者认为多数DES术后患者可考虑短期DAPT。

要点

  • 长期DAPT较短期增加大出血(OR 1.78)和非心源性死亡(OR 1.63)。
  • 标准DAPT较短期增加任何出血(OR 1.39)。
  • ACS患者短期与标准DAPT疗效和安全性相似。

核心结论

  • 在所有临床表现的患者中,与短期DAPT(氯吡格雷)相比,长期DAPT导致更高的大出血和非心源性死亡率,标准DAPT与任何出血风险增加相关。
  • 对于ACS患者,短期DAPT与标准DAPT的疗效和安全性相似。
  • 对于植入新一代DES的患者,长期DAPT的全因死亡率高于短期DAPT。
  • 尽管最佳DAPT时程应考虑个体缺血和出血风险,但结合直接和间接比较证据,本研究提示多数DES术后患者可考虑短期DAPT。

研究设计与样本

  • 系统综述与网络Meta分析,纳入比较短期(<6个月)、标准(12个月)和长期(>12个月)DAPT的随机对照试验。
  • 检索Medline、Embase、Cochrane Library、PubMed、Web of Science、ClinicalTrials.gov和Clinicaltrialsregister.eu,时间范围为1983年6月至2018年4月。
  • 共纳入17项研究,n=46 864。

主要发现

  • 与短期DAPT相比,长期DAPT的大出血发生率更高(OR 1.78,95%CI 1.27-2.49),非心源性死亡发生率更高(OR 1.63,95%CI 1.03-2.59)。
  • 与短期DAPT相比,标准DAPT的任何出血发生率更高(OR 1.39,95%CI 1.01-1.92)。
  • 其他主要终点未见明显差异。
  • 敏感性分析显示,与短期或标准DAPT相比,≥18个月DAPT的非心源性死亡和出血风险进一步增加。
  • 亚组分析中,植入新一代DES的患者长期DAPT的全因死亡率高于短期DAPT(OR 1.99,95%CI 1.04-3.81);ACS患者和植入新一代DES的患者中,短期DAPT与标准DAPT的疗效和安全性相似。

关键数值与推荐

  • 长期DAPT vs 短期DAPT:大出血OR 1.78(95%CI 1.27-2.49),非心源性死亡OR 1.63(95%CI 1.03-2.59)。
  • 标准DAPT vs 短期DAPT:任何出血OR 1.39(95%CI 1.01-1.92)。
  • 新一代DES亚组:长期DAPT vs 短期DAPT全因死亡OR 1.99(95%CI 1.04-3.81)。

临床怎么用

  • 作者建议,结合直接和间接比较证据,多数DES术后患者可考虑短期DAPT。
  • 作者指出,最佳DAPT时程应结合个体缺血和出血风险评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of standard term (12 months) or long term (>12 months) dual antiplatelet therapy (DAPT) versus short term (<6 months) DAPT after percutaneous coronary intervention (PCI) with drug-eluting stent (DES). DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Relevant studies published between June 1983 and April 2018 from Medline, Embase, Cochrane Library for clinical trials, PubMed, Web of Science, ClinicalTrials.gov, and Clinicaltrialsregister.eu. REVIEW METHODS: Randomised controlled trials comparing two of the three durations of DAPT (short term, standard term, and long term) after PCI with DES were included. The primary study outcomes were cardiac or non-cardiac death, all cause mortality, myocardial infarction, stent thrombosis, and all bleeding events. RESULTS: 17 studies (n=46 864) were included. Compared with short term DAPT, network meta-analysis showed that long term DAPT resulted in higher rates of major bleeding (odds ratio 1.78, 95% confidence interval 1.27 to 2.49) and non-cardiac death (1.63, 1.03 to 2.59); standard term DAPT was associated with higher rates of any bleeding (1.39, 1.01 to 1.92). No noticeable difference was observed in other primary endpoints. The sensitivity analysis revealed that the risks of non-cardiac death and bleeding were further increased for ≥18 months of DAPT compared with short term or standard term DAPT. In the subgroup analysis, long term DAPT led to higher all cause mortality than short term DAPT in patients implanted with newer-generation DES (1.99, 1.04 to 3.81); short term DAPT presented similar efficacy and safety to standard term DAPT with acute coronary syndrome (ACS) presentation and newer-generation DES placement. The heterogeneity of pooled trials was low, providing more confidence in the interpretation of results. CONCLUSIONS: In patients with all clinical presentations, compared with short term DAPT (clopidogrel), long term DAPT led to higher rates of major bleeding and non-cardiac death, and standard term DAPT was associated with an increased risk of any bleeding. For patients with ACS, short term DAPT presented similar efficacy and safety with standard term DAPT. For patients implanted with newer-generation DES, long term DAPT resulted in more all cause mortality than short term DAPT. Although the optimal duration of DAPT should take personal ischaemic and bleeding risks into account, this study suggested short term DAPT could be considered for most patients after PCI with DES, combining evidence from both direct and indirect comparisons. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42018099519.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Yin SH, Xu P, Wang B, et al. Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis. BMJ. 2019. PMID: 31253632. doi:10.1136/bmj.l2222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。